Table 3 Treatment-emergent adverse events in patients (n = 81)
No. (%) | |||
---|---|---|---|
Grade 1 or 2 | Grade 3 | Grade 4 | |
Neutropenia | 32 (40%) | 38 (47%) | 5 (6%) |
Leukopenia | 57 (70%) | 16 (20%) | 0 |
Diarrhea | 56(69%) | 14 (17%) | 0 |
Anemia | 52 (64%) | 3 (4%) | 0 |
Oral mucositis | 47 (58%) | 4 (5%) | 0 |
Nausea | 26 (32%) | 0 | 0 |
Rash | 22 (27%) | 1 (1%) | 0 |
Hypokalemia | 20 (25%) | 1 (1%) | 0 |
γ-glutamyl transferase | |||
Increased | 15 (19%) | 1 (1%) | 0 |
Fatigue | 13 (16%) | 1 (1%) | 0 |
Hyponatremia | 13 (16%) | 0 | 0 |
Vomiting | 13 (16%) | 0 | 0 |
Headache | 11 (14%) | 0 | 0 |
Hypocalcemia | 10 (12%) | 0 | 0 |
Platelet count decreased | 9 (11%) | 0 | 0 |
Dizziness | 9 (11%) | 0 | 0 |
Hypercholesteremia | 7 (9%) | 1 (1%) | 0 |
Alopecia | 5 (6%) | 0 | 0 |
Alanine aminotransferase | |||
Increased | 2 (2%) | 2 (2%) | 0 |
Aspartate aminotransferase | |||
Increased | 0 | 0 | 1 (1%) |